UNIONDALE, NY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, announced today that they will be participating in Renmark Financial Communications Inc’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Thursday, September 4, 2025, at 12:00 pm EDT. ProPhase Labs Inc. welcomes stakeholders, investors and other individual followers to register and attend this live event.
The presentation will feature Ted Karkus, Chairman and Chief Executive Officer. Topics to be covered will include a general overview of the Company as well as several important initiatives including the crypto treasury strategy, potential significant liquidity events that are well underway and the cancellation of the Equity Line of Credit (ELOC). The investor presentation will be followed by a live Q&A. Investors interested in participating in this event will need to register using the link below. As a reminder, registration for the live event may be limited but access to the replay after the event will be on the Company’s Investor website.
Thursday, September 4, 2025:
About ProPhase Labs Inc.
ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and consumer products company. Our mission is to build a healthier world through bold innovation and actionable insight. We’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, groundbreaking diagnostic development – such as our potentially life-saving test for the early detection of esophageal cancer – and a world class direct-to-consumer marketing platform for cutting edge OTC dietary supplements. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ valuable subsidiaries, their synergies, and significant growth underscore our potential for long-term value. www.ProPhaseLabs.com
Media Relations and Institutional Investor Contact:
ProPhase Labs, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Retail Investor Relations Contact:
Renmark Financial Communications Inc.
John Boidman: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel.: (416) 644-2020 or (212) 812-7680
www.renmarkfinancial.com
| Last Trade: | US$0.21 |
| Daily Change: | 0.02 13.26 |
| Daily Volume: | 1,559,544 |
| Market Cap: | US$8.520M |
November 19, 2025 October 29, 2025 October 24, 2025 October 22, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
